WAYNE GOODMAN to Anxiety Disorders
This is a "connection" page, showing publications WAYNE GOODMAN has written about Anxiety Disorders.
Connection Strength
2.674
-
The anxiety severity interview for children and adolescents: an individualized repeated measure of anxiety severity. Clin Psychol Psychother. 2014 Nov-Dec; 21(6):525-35.
Score: 0.295
-
SSRI adverse events: how to monitor and manage. Int Rev Psychiatry. 2008 Apr; 20(2):203-8.
Score: 0.202
-
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 2005 Aug; 87(2-3):161-7.
Score: 0.168
-
Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry. 2005 Apr-Jun; 17(2):71-5.
Score: 0.164
-
Selecting pharmacotherapy for generalized anxiety disorder. J Clin Psychiatry. 2004; 65 Suppl 13:8-13.
Score: 0.151
-
Alterations in attentional processing in youth with misophonia: A phenotypical cross-comparison with anxiety patients. J Affect Disord. 2024 02 15; 347:429-436.
Score: 0.150
-
Parent-Led Cognitive Behavioral Teletherapy for Anxiety in Autistic Youth: A Randomized Trial Comparing Two Levels of Therapist Support. Behav Ther. 2024 May; 55(3):499-512.
Score: 0.147
-
Anger Outbursts in Youth with ASD and Anxiety: Phenomenology and Relationship with Family Accommodation. Child Psychiatry Hum Dev. 2024 Oct; 55(5):1259-1268.
Score: 0.141
-
The Relationship of Family Accommodation with Pediatric Anxiety Severity: Meta-analytic Findings and Child, Family and Methodological Moderators. Child Psychiatry Hum Dev. 2021 02; 52(1):1-14.
Score: 0.123
-
The Impact of Comorbidity on Cognitive-Behavioral Therapy Response in Youth with Anxiety and Autism Spectrum Disorder. Child Psychiatry Hum Dev. 2020 08; 51(4):625-635.
Score: 0.119
-
Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis. J Anxiety Disord. 2019 12; 68:102149.
Score: 0.112
-
Chinese Therapists' Beliefs About Exposure Therapy for Anxiety and Obsessive-Compulsive Disorders. J Psychiatr Pract. 2019 05; 25(3):179-185.
Score: 0.109
-
Clinicians' perspectives of interfering behaviors in the treatment of anxiety and obsessive-compulsive disorders in adults and children. Cogn Behav Ther. 2020 01; 49(1):81-96.
Score: 0.108
-
Cognitive Behavioral Therapy for Childhood Anxiety Disorders: a Review of Recent Advances. Curr Psychiatry Rep. 2018 07 28; 20(8):65.
Score: 0.103
-
D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data. JAMA Psychiatry. 2017 05 01; 74(5):501-510.
Score: 0.095
-
A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
Score: 0.051
-
Where does obsessive-compulsive disorder belong in DSM-V? Depress Anxiety. 2008; 25(4):336-47.
Score: 0.050
-
Reliability and validity of the Yale Global Tic Severity Scale. Psychol Assess. 2005 Dec; 17(4):486-91.
Score: 0.043
-
The clinical presentation of major depressive disorder in youth with co-occurring obsessive-compulsive disorder. J Affect Disord. 2024 Mar 15; 349:349-357.
Score: 0.038
-
Predictors and Moderators of Treatment Outcomes for Anxious Children Randomized to Computer-Assisted Cognitive Behavioral Therapy or Standard Community Care. J Child Adolesc Psychopharmacol. 2023 10; 33(8):316-324.
Score: 0.037
-
Family Accommodation in Children and Adolescents With Misophonia. Behav Ther. 2024 May; 55(3):595-604.
Score: 0.037
-
COVID-19-related intrusive thoughts and associated ritualistic behaviors. Bull Menninger Clin. 2023; 87(3):225-249.
Score: 0.035
-
Clinical characteristics, impairment, and psychiatric morbidity in 102 youth with misophonia. J Affect Disord. 2023 03 01; 324:395-402.
Score: 0.035
-
Primary Outcomes for Adults Receiving the Unified Protocol after Hurricane Harvey in an Integrated Healthcare Setting. Community Ment Health J. 2022 11; 58(8):1522-1534.
Score: 0.033
-
Age moderated-anxiety mediation for multimodal treatment outcome among children with obsessive-compulsive disorder: An evaluation with correspondence analysis. J Affect Disord. 2021 03 01; 282:766-775.
Score: 0.031
-
Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). Neuropsychopharmacology. 2020 09; 45(10):1656-1663.
Score: 0.029
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
Score: 0.029
-
Predictors of treatment outcome for youth receiving intensive residential treatment for obsessive-compulsive disorder (OCD). Cogn Behav Ther. 2020 07; 49(4):294-306.
Score: 0.028
-
Suicidality as a possible side effect of antidepressant treatment. J Clin Psychiatry. 2004 Jun; 65(6):742-9.
Score: 0.010